WELCOME

Oncology/Hematology of Loudoun and Reston is proud to celebrate 20 years of service to the community. We are a private medical group practice specializing in medical oncology and hematology.

YOUR TEAM

Meet the caring professionals involved in your care.

TYPES OF CANCER

Cancer is not one disease, but many diseases that occur in different areas.

CANCER TREATMENT

Choice of cancer treatment is influenced by several factors.

CLINICAL TRIALS

Clinical trials are studies that evaluate the effectiveness of new drugs.

Click here to access our Patient Portal

sponsored by the Loudoun Bible Church. This session will feature specialists discussing colorectal cancer.

The event is free and open to the public!

sponsored by the Loudoun Bible Church. This session will feature specialists discussing colorectal cancer.

The event is free and open to the public!

sponsored by the Loudoun Bible Church. This session will feature specialists discussing colorectal cancer.

The event is free and open to the public!

Delivering Exceptional Care to Cancer Patients for 20 Years

OUR MISSION

Oncology/Hematology of Loudoun and Reston, P.C., founded in 1997, specializes in the diagnosis and treatment of adults with cancer or hematological abnormalities. State of the art treatment is administered by knowledgeable and professional staff in a warm, compassionate atmosphere. Patients, family members and caregivers are treated with dignity and respect towards the common goals of health and healing.

“A good practice treats the disease…
A great practice treats the patient.”

Medical oncologists and hematologists are trained and board-certified in internal medicine, followed by additional training and certification in medical oncology (cancer medicine) or hematology (benign and malignant blood disorders) or both. The clinical staff works in close collaboration with other physicians who are involved in your care. We offer state-of-the-art treatment, including cancer chemotherapy and immunotherapy.

Our practice is dedicated to providing quality cancer care in a caring, compassionate setting in your community. We have three locations to serve you: Lansdowne, Stone Springs, and Reston.

MEET OUR PHYSICIANS

Dr. Mei Firestone joined the practice in 2015. She completed her undergraduate degree at Washington University in St. Louis, and earned her medical degree from Georgetown University School of Medicine. Dr. Firestone has a special interest in breast cancer.

Dr. Rajendra founded the practice. He has been practicing medical oncology and hematology in Loudoun County since 1991.

Becoming a doctor was an easy choice for Dr. Manoel Moraes, who finds a great source of inspiration in his patients.

Dr. Jeffrey White became interested in medicine as an engineering student at Cornell University.

Dr. Ali has been a practicing hematologist and medical oncologist in Virginia since completing his fellowship at the Monter Cancer Center of the North-Shore Long Island Jewish Health System in 2010.

CONGRATULATIONS TOP DOCTORS

Dr. Rajendra

Washingtonian Top Doctor 2016

Dr. Moraes and Dr. Rajendra

Northern Virginia Magazine Top Doctors 2017

OUR LOCATIONS

APPOINTMENTS

Hours of Operation:
Monday-Friday 9:00 a.m. to 4:30 p.m.
Existing patients can check their appointments through our Patient Portal,

You may become our patient either by making the appointment yourself or through a physician referral. We also welcome the opportunity to provide second opinions.

CANCER NEWS

Keytruda® Active in Small Cell Lung Cancer

Recently updated findings from the phase 1b KEYNOTE-028 study investigating the use of Keytruda® (pembrolizumab) in small cell lung cancer (SCLC) were recently presented at the 17th World Conference on Lung Cancer. Lung cancer remains the leading cause of cancer-related deaths worldwide. In the United States, SCLC accounts for 10-20% of all lung cancers. Although progress … Continue reading “Keytruda® Active in Small Cell Lung Cancer”

read more

Rubraca™ Is Granted Accelerated Approval for Advanced Ovarian Cancer

The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Rubraca™ (rucaparib) for the treatment of women with advanced ovarian cancer who have been treated with two or more chemotherapies and whose tumors have a BRCA gene mutation. Each year in the U.S. roughly 22,000 women are diagnosed with ovarian cancer and more … Continue reading “Rubraca™ Is Granted Accelerated Approval for Advanced Ovarian Cancer”

read more

5-Year Survival Improved with Early Use of Jakafi® in Myelofibrosis

An analysis of 5-year data from two large clinical trials provide conclusive support that treatment with Jakafi® (ruxolitinib) improves long-term survival, compared to other treatment options for patients with myelofibrosis. Perhaps even more importantly, the data suggests that treatment with Jakafi should be used much earlier in the course of a patient’s disease because it … Continue reading “5-Year Survival Improved with Early Use of Jakafi® in Myelofibrosis”

read more

Tagrisso®: New Standard of Care for Certain Lung Cancer

Treatment with the targeted agent Tagrisso (osimertinib) significantly delayed cancer progression, and resulted in fewer side effects, than standard chemotherapy for patients with advanced non-small cell lung cancer (NSCLC) whose cancer had progressed following prior therapy with an epidermal growth factor receptor (EGFR) inhibitor. Lung cancer remains the leading cause of cancer-related deaths in the … Continue reading “Tagrisso®: New Standard of Care for Certain Lung Cancer”

read more

Interferon No Better Than Hydroxyurea and Associated with Worse Side Effects in Polycythemia Vera and Essential Thrombocythemia

The use of interferon as initial therapy in MPN is associated with worsening side effects the longer it is used for treatment. These results were recently presented at the 2016 annual meeting of the American Society of Hematology. Myeloproliferative neoplasms (MPNs) are a related group of blood cancers. In these disorders, the bone marrow cells … Continue reading “Interferon No Better Than Hydroxyurea and Associated with Worse Side Effects in Polycythemia Vera and Essential Thrombocythemia”

read more

Gazyva® Improves Outcomes Compared to Rituxan® in Untreated Follicular Lymphoma

Treatment including the targeted agent Gazyva (obinutuzumab) delays cancer progression for a longer period of time than treatment with Rituxan (rituximab) among patients with follicular lymphoma who have not received prior therapy. These results were recently presented at a plenary session of the 2016 annual meeting of the American Society of Hematology (ASH). Follicular lymphoma … Continue reading “Gazyva® Improves Outcomes Compared to Rituxan® in Untreated Follicular Lymphoma”

read more

FDA Grants Iclusig® Expanded Approval for CML

The United States Food and Drug Administration (FDA) has granted Iclusig® (ponatinib) approval to treat all phases of chronic myeloid leukemia (CML) in adults, as well as Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ALL) who are not eligible for treatment with another tyrosine kinase inhibitor. The approval indication also includes adults with T3151-positive CML and T3151-positive … Continue reading “FDA Grants Iclusig® Expanded Approval for CML”

read more

Should HER2 Testing Be Routinely Performed in Patients with Gastric Cancer?

The short answer is yes! New evidence-based guidelines for human epidermal growth factor receptor 2 (HER2) testing in advanced gastric and gastroesophageal adenocarcinoma (GEA) have been released jointly by the College of American Pathologists (CAP), American Society for Clinical Pathology (ASCP), and American Society of Clinical Oncology (ASCO). Currently, HER2 is the only marker that can be … Continue reading “Should HER2 Testing Be Routinely Performed in Patients with Gastric Cancer?”

read more

ASCO Recommends Early Integration of Palliative Care for Advanced Cancers

The American Society of Clinical Oncology (ASCO) has updated its guidelines on the integration of palliative care for patients diagnosed with advanced cancer, as well as their caretakers. In essence, the guidelines state that palliative care should be administered as early as possible for all patients diagnosed with advanced cancers, alongside their active treatment, as …

read more

SEE MY CHART

Leesburg or Sterling

PAY MY BILL

info@gmail.com

info@yahoomail.com